Skip to Content


In the US, Empagliflozin (empagliflozin systemic) is a member of the drug class SGLT-2 inhibitors and is used to treat Cardiovascular Risk Reduction and Diabetes - Type 2.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Oral antidiabetic agent: sodium-glucose co-transporter 2 (SGLT2) inhibitor

Chemical Name

(1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-{[(3S)-oxolan-3-yl]oxy}phenyl)methyl]phenyl}-D-glucitol (WHO)

Foreign Names

  • Empagliflozinum (Latin)
  • Empagliflozin (German)
  • Empagliflozine (French)
  • Empagliflozina (Spanish)

Generic Names

  • Empagliflozin (OS: USAN, JAN)
  • UNII-HDC1R2M35U (IS)
  • Empagliflozin (PH: JP XVI)

Brand Names

  • Glyxambi (Empagliflozin and Linagliptin)
    Boehringer Ingelheim Pharmaceuticals, United States
  • Jardiance
    Boehringer Ingelheim, Bosnia & Herzegowina; Boehringer Ingelheim, Switzerland; Boehringer Ingelheim, Denmark; Boehringer Ingelheim, Finland; Boehringer Ingelheim, United Kingdom; Boehringer Ingelheim, Croatia (Hrvatska); Boehringer Ingelheim, Ireland; Boehringer Ingelheim, Poland; Boehringer Ingelheim, Sweden; Boehringer Ingelheim, Slovenia; Boehringer Ingelheim, Slovakia; Boehringer Ingelheim EspaƱa, Spain; Boehringer Ingelheim International, Austria; Boehringer Ingelheim International, Germany; Boehringer Ingelheim Pharmaceuticals, United States; Boehringer Ingelheim Singapore, Singapore
  • Jardiance Met (Empagliflozin and Metformin)
    Boehringer Ingelheim, Switzerland
  • Synjardy (Empagliflozin and Metformin)
    Boehringer Ingelheim, United Kingdom; Boehringer Ingelheim, Slovenia; Boehringer Ingelheim International, Germany; Boehringer Ingelheim Pharmaceuticals, United States


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.